LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akciju saraksts・CytoSorbents Corp

CytoSorbents Corp

Slēgts

SektorsVeselības aprūpe

0.56 -8.2

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.56

Max

0.61

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.3M -5.5M
Pārdošana	-251K 9.2M
Peļņas marža	-59.526
Darbinieki	129
EBITDA	-766K -3.7M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+22.95% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 13. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.4M 39M
Iepriekšējā atvēršanas cena	8.76
Iepriekšējā slēgšanas cena	0.56

Ziņu noskaņojums

By Acuity

93%

337 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

0.705 / 0.771 Atbalsts un pretestība

CytoSorbents Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. maijs 22:15 UTC

Iegādes, apvienošanās, pārņemšana

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026. g. 11. maijs 23:46 UTC

Tirgus saruna

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026. g. 11. maijs 23:44 UTC

Tirgus saruna

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026. g. 11. maijs 23:33 UTC

Tirgus saruna

Gold Rises on Possible Position Adjustments -- Market Talk

2026. g. 11. maijs 22:37 UTC

Tirgus saruna

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026. g. 11. maijs 22:32 UTC

Peļņas

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026. g. 11. maijs 22:02 UTC

Tirgus saruna

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026. g. 11. maijs 21:49 UTC

Peļņas

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026. g. 11. maijs 21:42 UTC

Tirgus saruna

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026. g. 11. maijs 21:31 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026. g. 11. maijs 21:23 UTC

Iegādes, apvienošanās, pārņemšana

CSG Systems Sale to NEC Gets CFIUS Clearance

2026. g. 11. maijs 21:12 UTC

Peļņas

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026. g. 11. maijs 21:12 UTC

Peļņas

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026. g. 11. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 11. maijs 20:44 UTC

Peļņas

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026. g. 11. maijs 20:43 UTC

Peļņas

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026. g. 11. maijs 20:32 UTC

Peļņas

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026. g. 11. maijs 20:32 UTC

Peļņas

CleanSpark 2Q Rev $136.4M >CLSK

2026. g. 11. maijs 20:30 UTC

Peļņas

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Cont Ops EPS $2.24 >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Rev $1.6B >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Adj EPS $2.83 >STE

2026. g. 11. maijs 20:22 UTC

Karstas akcijas

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026. g. 11. maijs 19:37 UTC

Peļņas

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026. g. 11. maijs 19:32 UTC

Tirgus saruna

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytoSorbents Corp Prognoze

Cenas mērķis

By TipRanks

22.95% augšup

Prognoze 12 mēnešiem

Vidējais 0.75 USD 22.95%

Augstākais 0.75 USD

Zemākais 0.75 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytoSorbents Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytoSorbents Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.705 / 0.771Atbalsts un pretestība

All events are bearish.

Noskaņojums

By Acuity

337 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.